Cargando…

Analysis of US Food and Drug Administration Breast Implant Postapproval Studies Finding an Increased Risk of Diseases and Cancer: Why the Conclusions Are Unreliable

Detalles Bibliográficos
Autor principal:	Swanson, Eric
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2019
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6392206/ https://www.ncbi.nlm.nih.gov/pubmed/30730863 http://dx.doi.org/10.1097/SAP.0000000000001732

Ejemplares similares

Characteristics of Preapproval and Postapproval Studies of Vaccines Granted Accelerated Approval by the US Food and Drug Administration
por: Egilman, Alexander, et al.
Publicado: (2021)

Plastic Surgeons Defend Textured Breast Implants at 2019 U.S. Food and Drug Administration Hearing: Why It Is Time to Reconsider
por: Swanson, Eric
Publicado: (2019)

Analysis of Postapproval Clinical Trials of Therapeutics Approved by the US Food and Drug Administration Without Clinical Postmarketing Requirements or Commitments
por: Skydel, Joshua J., et al.
Publicado: (2019)

Comparison of Duration of Postapproval vs Pivotal Trials for Therapeutic Agents Granted US Food and Drug Administration Accelerated Approval, 2009-2018
por: Wallach, Joshua D., et al.
Publicado: (2021)

Why are psychiatric imaging methods clinically unreliable? Conclusions and practical guidelines for authors, editors and reviewers
por: Borgwardt, Stefan, et al.
Publicado: (2012)

Feasibility of Using Real-world Data to Emulate Postapproval Confirmatory Clinical Trials of Therapeutic Agents Granted US Food and Drug Administration Accelerated Approval
por: Wallach, Joshua D., et al.
Publicado: (2021)

Adulterated and Unreliable Drugs
Publicado: (1883)

The progress of postapproval clinical studies on Sabin IPV
por: Shi, Li, et al.
Publicado: (2021)

Why the Watchdog Won’t Bite: U.S. Food and Drug Administration Challenges
por: Lex, Joe
Publicado: (2016)

Leadless pacemaker implant in patients with pre‐existing infections: Results from the Micra postapproval registry
por: El‐Chami, Mikhael F., et al.
Publicado: (2019)

Six‐month outcomes in postapproval HeartMate3 patients: A single‐center US experience
por: Bansal, Aditya, et al.
Publicado: (2022)

Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: systematic review
por: Pease, Alison M, et al.
Publicado: (2017)

Two is better than one: Using a single emotion lexicon can lead to unreliable conclusions
por: Czarnek, Gabriela, et al.
Publicado: (2022)

Strengthening postapproval oversight in research ethics committees: Challenges and solutions
por: Shetty, Yashashri Chandrakant, et al.
Publicado: (2023)

Why is AAV FVIII gene therapy not approved by the US Food and Drug Administration yet?
por: Arruda, Valder R.
Publicado: (2021)

Results of the combined U.S. multicenter postapproval study of the Nit‐Occlud PDA device for percutaneous closure of patent ductus arteriosus
por: Kobayashi, Daisuke, et al.
Publicado: (2018)

Finding low CHA2DS2-VASc scores unreliable? Why not give morphological and hemodynamic methods a try?
por: Sun, YiRen, et al.
Publicado: (2023)

Unreliable Medical Certificates
Publicado: (1898)

Unreliability of the Fixed Bridge
Publicado: (1904)

Unsafe, Unscientific, Unreliable!
Publicado: (1899)

Patient burden and clinical advances associated with postapproval monotherapy cancer drug trials: a retrospective cohort study
por: Carlisle, Benjamin Gregory, et al.
Publicado: (2020)

Use of a Spin Strategy Can Result in Unreliable Research Findings
por: Okumura, Yasuyuki
Publicado: (2017)

How to Respond to the US Food and Drug Administration's Report on Squamous Cell Carcinoma in Breast Implant Capsules
por: Teitelbaum, Steven
Publicado: (2023)

DuraSeal Exact Is a Safe Adjunctive Treatment for Durotomy in Spine: Postapproval Study
por: Kim, Kee D., et al.
Publicado: (2018)

Postapproval trials versus patient registries: comparability of advanced melanoma patients with brain metastases
por: Ismail, Rawa K., et al.
Publicado: (2020)

Cyberpharmacies and the role of the US Food And Drug Administration
por: Henney, Jane E
Publicado: (2001)

The US Food and Drug Administration’s Intersection with Dermatology
por: Luke, Markham C.
Publicado: (2022)

Process of drug registration in Israel: the correlation between the number of discussions within the Ministry of Health and postapproval variations by EMA and/or FDA
por: Hiayev, Stephany, et al.
Publicado: (2023)

Offline: The danger of unreliable narrators
por: Horton, Richard
Publicado: (2021)

The Unreliability of Online Review Mechanisms
por: Narciso, M.
Publicado: (2022)

EFSA’s toxicological assessment of aspartame: was it even-handedly trying to identify possible unreliable positives and unreliable negatives?
por: Millstone, Erik Paul, et al.
Publicado: (2019)

U.S. sperm trend conclusions.
por: James, W H
Publicado: (1999)

Association of Fluoroquinolone Prescribing Rates With Black Box Warnings from the US Food and Drug Administration
por: Sankar, Ashwini, et al.
Publicado: (2021)

The Unreliability of the Microscope in the Diagnosis of Malignant Disease
por: Whiteford, C. Hamilton
Publicado: (1902)

An Examination of the Neural Unreliability Thesis of Autism
por: Butler, John S., et al.
Publicado: (2017)

The Cunningham Panel is an unreliable biological measure
por: Bejerot, Susanne, et al.
Publicado: (2019)

Approximate Minimum Selection with Unreliable Comparisons
por: Leucci, Stefano, et al.
Publicado: (2021)

Characteristics of Recent Generic Drug Approvals by the US Food and Drug Administration
por: Jiao, Kuo, et al.
Publicado: (2019)

Use of Extrapolation in New Drug Approvals by the US Food and Drug Administration
por: Feldman, Daniel, et al.
Publicado: (2022)

The U.S. Food and Drug Administration: Drug Information Resource for Formulary Recommendations
por: Marchand, Heidi C., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_39rgdoe4leg04s64hqejpbie49